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Autologous stem cell transplant (ASCT), is the
treatment
of
choice
for
aggressive,
relapsed/refractory Non- Hodgkin’s and Hodgkin’s
Lymphomas [1, 2]. In patients aged less than 65
years, 40-45% achieve cure with this form of
treatment. The duration of remission post-transplant
depends upon the histological subtype, prior
treatment and the response to salvage therapy. In
Pakistan, the common lymphomas for which patients
receive treatment include: Diffuse Large B Cell
Lymphoma (DLBCL), Mantle cell Lymphoma,
Follicular Lymphoma and Hodgkin’s Lymphoma [3].
Of these, ASCT is commonly performed for DLBCL
and Hodgkin’s Lymphoma in second complete
remission [4].
Based on the opinion that ASCT can potentially cure
50% of patients who relapse but are chemosensitive,
this procedure was performed in a cohort of patients
who partially responded to chemotherapy. Philip et al
in 1998 [5] reported that 76% of the patients
remained disease free with a six year survival of 75%
post ASCT. The Non-Hodgkin’s Lymphoma
Cooperative Study in 1993 showed a 5 year disease
free survival of 36% (n=21 patients) [6]. This
translated as a potential cure of approximately one in
three patients with PR after ASCT. Hamdani M et al
in 2014 [7], reported important outcomes on n=516
DLBCL patients with respect to Rituximab based
therapies and ASCT. The observations included: a)
patients receiving Rituximab based therapy and
experiencing late relapse (> 1 year after treatment),
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have excellent response to ASCT; b) In patients with
early relapse (within one year of treatment with
Rituximab based regimens), ASCT can confer
durable disease control; c) In patients who have
refractory disease but respond to salvage therapies,
ASCT is the only potentially curative treatment
option; however a fourth observation included that a
subset of patients relapsed within 6-9 months of
transplant. This led to the inference of maintenance
Rituximab. Gisselbrecht C et al in 2012 [8], after
performing ASCT and randomly assigning patients to
two groups of cohort (n=122 patients who received
Rituximab, n=120 patients who did not receive
Rituximab) concluded that there was no difference
between the maintenance group and control group
and did not recommend maintenance post-transplant.
A study done by Zhang W et al [9] demonstrated that
ASCT in combination with Rituximab in vivo
purging followed by maintenance Rituximab
prolongs progression free survival and overall
survival. However this was a cohort of n=12 young
patients with DLBCL. Therefore, the current
recommendation for relapsed/refractory DLBCL
remains to be ASCT in transplant eligible patients
with no role of maintenance Rituximab.
Most patients with Hodgkin’s Lymphoma (HL)
achieve long term remission with chemo or
radiotherapy. However, 10% - 30% of patients
progress or relapse depending on the stage. ASCT
can cure 50% of these patients. In the remaining
50%, treatment of HL remains to be a challenge
[10,11]. The use of Brentuximab vedotin (anti-CD30)
in early phase I trials did not demonstrate any clinical
significance [12, 13]. Phase II trials however,
demonstrated satisfactory results. The German
Hodgkin Study Group showed an overall response
rate (ORR) of 60% in n=45, heavily pretreated
patients [14]. Due to this increased ORR and
tolerable safety profile of the drug, FDA granted an
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accelerated approval for the treatment of HL in
patients who relapse after ASCT or in patients
ineligible for transplant.
The National
Comprehensive Cancer Network guideline includes
Brentuximab for the same. Brentuximab has also
been used as a bridge to ASCT in patients who fail
standard and salvage treatments [15].
Moving forward, to further improve outcomes after
ASCT in relapsed/refractory Lymphomas, efforts
need to be focused on evaluating novel consolidation
or maintenance strategies, possibly with agents not
used in induction/salvage therapies. The current
standard of care remains to be high dose
chemotherapy followed by autologous stem cell
transplant and immunotherapies cannot be used as an
alternative to transplant.
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